Explore

Trendline Trendline
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Trendline Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results
Trendline Trendline
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Trendline Trendline
Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy
Trendline Trendline
Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026
Trendline Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Trendline Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Trendline Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments
Trendline Trendline
Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments
Trendline Trendline
Coya Therapeutics Reports Financial Results and Advances ALS Treatment

Coya Therapeutics Reports Financial Results and Advances ALS Treatment

Coya Therapeutics Reports Financial Results and Advances ALS Treatment